Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Cuba credits two drugs with slashing coronavirus death toll

Published 05/22/2020, 06:06 PM
Updated 05/22/2020, 06:35 PM
© Reuters. Coronavirus disease (COVID-19) outbreak, in Havana

By Sarah Marsh

HAVANA (Reuters) - Communist-run Cuba said this week that use of two drugs produced by its biotech industry that reduce hyper-inflammation in seriously ill COVID-19 patients has sharply curbed its coronavirus-related death toll.

Health authorities have reported just two virus-related deaths over the past nine days among more than 200 active cases on the Caribbean's largest island, a sign they may have the worst of the outbreak under control.

The government, which hopes to increase its biopharmaceutical exports, has touted various drugs it produces for helping prevent infection with the new coronavirus and treating the COVID-19 disease it causes.

It ascribes the recent reduction in deaths of severely ill COVID-19 patients largely to the use beginning in April of two drugs that appear to help calm the "cytokine storm," a dangerous overresponse by the immune system in which it attacks healthy tissue as well as the invading virus.

One is itolizumab, a monoclonal antibody produced in Cuba and elsewhere. The other is a peptide that Cuba says its biotech industry discovered and has been testing for rheumatoid arthritis in Phase II clinical trials.

"Some 80 percent of patients who end up in critical condition are dying. In Cuba, with the use of these drugs, 80 percent of those who end up in critical or serious condition are being saved," President Miguel Diaz-Canel said on Thursday in a meeting shown on state television.

Scientists caution that large placebo-controlled studies are needed to assess the safety and efficacy of these drugs for treating COVID-19.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

But Cuba's experimental treatments have helped it achieve an overall COVID-19 death rate of 4.2%, compared with the regional and global averages of 5.9% and 6.6%, respectively, health authorities say.

Fatality rates depend on many variables, including the rate of testing, quality of healthcare systems, and age and underlying health condition of the population.

Official data suggests that Cuba, with universal healthcare and a well-staffed care system, has done well in containing its outbreak. It has registered less than 20 cases per day over the past week, down from a peak of 50 to 60 in mid-April. In total, Cuba has reported 1,916 cases for a population of 11 million and 81 death.

That translates to an infection rate 0.71 per 100,000 inhabitants, compared with about 29 per 100,000 for the United States, according to a John's Hopkins University tally.

Swift action helped Cuba contain its outbreak. After closing borders, schools and public transportation in March, Cuba urged residents to stay home, made wearing of masks obligatory, and employed effective contact tracing to curb the virus spread.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.